Table 1.
Chronic Hepatitis Cohort Study hepatitis C virus cohort patient status on January 1, 2016
| Variables | Overall |
Died (All Cause) |
Liver Transplanta |
Achieved SVRb |
Still HCV Infected |
HCV Status Cannot Be Determined |
|---|---|---|---|---|---|---|
| N (Column%) |
n (row%) |
n (row%) |
n (row%) |
n (row%) |
n (row%) |
|
| 17,893 | 3871 (21.6%) | 555 (3.1%) | 3378 (18.9%) | 8906 (49.8%) | 1183 (6.6%) | |
| Birth year | ||||||
| 1965 through 1984 | 5985 (33.4) | 1054 (17.6) | 190 (3.2) | 1231 (20.6) | 3129 (52.3) | 381 (6.4) |
| 1945 through 1964 | 6682 (37.3) | 1882 (28.2) | 292 (4.4) | 1305 (19.5) | 2933 (43.9) | 270 (4.0) |
| Birth year ≤1944 | 1467 (8.2) | 657 (44.8) | 46 (3.1) | 180 (12.3) | 550 (37.5) | 34 (2.3) |
| Gender | ||||||
| Male | 10,862 (60.7) | 2684 (24.7) | 420 (3.9) | 1941 (17.9) | 5108 (47.0) | 709 (6.5) |
| Female | 7031 (39.3) | 1187 (16.9) | 135 (1.9) | 1437 (20.4) | 3798 (54.0) | 474 (6.7) |
| Race | ||||||
| Non-Hispanic white | 11,308 (63.2) | 2109 (18.7) | 357 (3.2) | 2403 (21.3) | 5518 (48.8) | 921 (8.1) |
| Non-Hispanic black | 4022 (22.5) | 1247 (31.0) | 115 (2.9) | 544 (13.5) | 1982 (49.3) | 134(3.3) |
| Other | 2563 (14.3) | 515 (20.1) | 83 (3.2) | 431 (16.8) | 1406 (54.9) | 128 (5.0) |
| Insurance status | ||||||
| Private | 8824 (49.3) | 1362 (15.4) | 179 (2.0) | 1959 (22.2) | 4641 (52.6) | 683 (7.7) |
| Medicaid | 2054(11.5) | 499 (24.3) | 38 (1.9) | 208 (10.1) | 1165 (56.7) | 144 (7.0) |
| Medicare | 5538 (31.0) | 1612 (29.1) | 326 (5.9) | 1054 (19.0) | 2365 (42.7) | 181 (3.3) |
| Other/unknown | 1477 (8.3) | 398 (26.9) | 12 (0.8) | 157 (10.6) | 735 (49.8) | 175 (11.8) |
| Income (estimated census tract geocode) | ||||||
| <$30,000 | 4258 (23.8) | 1172 (27.5) | 80 (1.9) | 578 (13.6) | 2137 (50.2) | 291 (6.8) |
| $30,000 to <50,00C | 8201 (45.8) | 1700 (20.7) | 237 (2.9) | 1585 (19.3) | 4110 (50.1) | 569 (6.9) |
| ≥$50,000 | 4850 (27.1) | 872 (18.0) | 212 (4.4) | 1159 (23.9) | 2345 (48.4) | 262 (5.4) |
| Not available | 584 (3.3) | 127 (21.7) | 26 (4.5) | 56 (9.6) | 314(53.8) | 61 (10.4) |
| Study site | ||||||
| Portland, OR | 4329 (24.2) | 577 (13.3) | 53 (1.2) | 809 (18.7) | 2633 (60.8) | 257 (5.9) |
| Honolulu, HI | 1564 (8.7) | 222 (14.2) | 25(1.6) | 292 (18.7) | 969 (62.0) | 56 (3.6) |
| Detroit, MI | 7402 (41.4) | 2288 (30.9) | 423 (5.7) | 1345 (18.2) | 3158 (42.7) | 188 (2.5) |
| Danville, PA | 4598 (25.7) | 784(17.1) | 54 (1.2) | 932 (20.3) | 2146 (46.7) | 682 (14.8) |
| Observation time in yearsc | ||||||
| Median | 5.9 | 4.8 | 6.6 | 2.9 | 7.5 | 4.4 |
| Range | 0.0–25.4 | 0.0–20.5 | 0.0–20.5 | 0.0–25.4 | 0.0–23.0 | 0.0–22.8 |
| Mean (SE) | 6.8 (0.0) | 5.8 (0.1) | 7.6 (0.2) | 4.6 (0.1) | 8.2 (0.1) | 5.5 (0.1) |
a
Liver transplant status identified by at least one of the following ICD-9 diagnosis or procedure codes: 996.82, 50.5, 50.51, 50.59, 47135, or 47136.
b
Defined as having more negative HCV RNA tests at least 12 wk after treatment as evidenced by available EHR laboratory data or provider documentation.
c
Observation defined as time from the first diagnosis of hepatitis C within the health system to the date of the first endpoint (death, liver transplant, SVR) or last encounter in the health system.